(APGE) Apogee Therapeutics, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.117m USD | Total Return: 101.1% in 12m
Avg Turnover: 54.5M
Warnings
Share dilution 19.7% YoY
High Debt while negative Cash Flow
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Shakeout
Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company focused on developing biologics for inflammatory and immunology (I&I) indications. The company’s pipeline utilizes extended half-life monoclonal antibodies (mAbs) designed for subcutaneous administration, targeting conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
The company’s lead candidate, Zumilokibart (APG777), is currently in Phase 2 clinical trials for atopic dermatitis. In the biotechnology sector, companies often utilize half-life extension technologies to reduce dosing frequency, which can improve patient compliance compared to existing therapies. This business model relies on high-stakes research and development cycles where value is primarily driven by clinical trial milestones and regulatory approvals.
Additional pipeline assets include APG279, APG273, and APG808, which target various Type 2 allergic diseases and respiratory conditions. To better understand how these clinical developments might impact the companys valuation, consider reviewing the detailed data on ValueRay. Founded in 2022 and headquartered in Massachusetts, Apogee operates within a competitive landscape of biologics aimed at large-market chronic inflammatory disorders.
- APG777 phase 2 clinical trial data determines competitive positioning against existing biologics
- Extended half-life technology differentiation impacts long-term market share and pricing power
- Clinical development costs and cash runway dictate future equity financing needs
- Regulatory milestones for subcutaneous delivery platforms drive near-term valuation shifts
- Expansion into asthma and COPD markets broadens total addressable revenue potential
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 8.85 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -234.5m > Net Income -274.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 32.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.7m) vs 12m ago 19.71% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.80 (Total Current Assets 1.07b - Total Current Liabilities 33.0m) / Total Assets 1.29b |
| B: -0.49 (Retained Earnings -635.9m / Total Assets 1.29b) |
| C: -0.30 (EBIT TTM -299.0m / Avg Total Assets 1.00b) |
| D: -16.81 (Book Value of Equity -636.6m / Total Liabilities 37.9m) |
| Altman-Z'' = -15.98 = D |
As of May 24, 2026, the stock is trading at USD 81.16 with a total of 330,182 shares traded.
Over the past week, the price has changed by +0.02%,
over one month by -10.50%,
over three months by +16.09% and
over the past year by +101.09%.
Apogee Therapeutics, Common has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy APGE.
- StrongBuy: 9
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118.8 | 46.4% |
Revenue TTM = 0.0 USD
EBIT TTM = -299.0m USD
EBITDA TTM = -297.3m USD
Long Term Debt = 4.91m USD (estimated: total debt 8.05m - short term 3.14m)
Short Term Debt = 3.14m USD (from shortTermDebt, last quarter)
Debt = 16.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.85m
Net Debt = -1.04b USD (calculated: Debt 16.9m - CCE 1.06b)
Enterprise Value = 5.07b USD (6.12b + Debt 16.9m - CCE 1.06b)
Interest Coverage Ratio = unknown (Ebit TTM -299.0m / Interest Expense TTM 0.0)
EV/FCF = -21.56x (Enterprise Value 5.07b / FCF TTM -235.4m)
FCF Yield = -4.64% (FCF TTM -235.4m / Enterprise Value 5.07b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 808k) / Revenue TTM)
Tobins Q-Ratio = 3.92 (Enterprise Value 5.07b / Total Assets 1.29b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -236.2m (EBIT -299.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 32.59 (Total Current Assets 1.07b / Total Current Liabilities 33.0m)
Debt / Equity = 0.01 (Debt 16.9m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 3.51 (negative EBITDA) (Net Debt -1.04b / EBITDA -297.3m)
Debt / FCF = 4.43 (negative FCF - burning cash) (Net Debt -1.04b / FCF TTM -235.4m)
Total Stockholder Equity = 841.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.35% (Net Income -274.6m / Total Assets 1.29b)
RoE = -18.59% (Net Income TTM -274.6m / Total Stockholder Equity 1.48b)
RoCE = -20.17% (EBIT -299.0m / Capital Employed (Equity 1.48b + L.T.Debt 4.91m))
RoIC = -27.62% (negative operating profit) (NOPAT -236.2m / Invested Capital 855.1m)
WACC = 10.44% (E(6.12b)/V(6.13b) * Re(10.47%) + D(16.9m)/V(6.13b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 15.22%
[DCF] Fair Price = unknown (Cash Flow -235.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.36 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.11 | Chg30d=+5.90% | Revisions=+0% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-1.17 | Chg30d=+4.12% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=-4.53 | Chg30d=+6.28% | Revisions=+0% | GrowthEPS=-7.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.22 | Chg30d=+4.27% | Revisions=-14% | GrowthEPS=-15.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -14%